Ozempic vs Mounjaro
The two biggest GLP-1 drugs compared head-to-head. Semaglutide vs tirzepatide — weight loss results, side effects, pricing in India, and how to decide which one is right for you.
Ozempic (semaglutide) targets GLP-1 receptors. Mounjaro (tirzepatide) targets both GLP-1 and GIP receptors. In head-to-head trials, Mounjaro produced more weight loss — about 21–22% vs 15–17% for Ozempic. But the choice isn't just about numbers.
Reading this to decide? Skip to the decision framework section for a practical guide based on your situation.
Dive deeper into the researchHead-to-head comparison
| Ozempic (Semaglutide) | Mounjaro (Tirzepatide) | |
|---|---|---|
| Mechanism | GLP-1 agonist | GLP-1 + GIP dual agonist |
| Weight loss | ~15–17% (at max dose) | ~21–22% (at max dose) |
| HbA1c reduction | 1.5–1.8% | 2.0–2.4% |
| Dosing | Weekly injection | Weekly injection |
| Max dose | 2.4 mg (Wegovy) | 15 mg |
| GI side effects | ~30–35% | ~25–30% (slightly fewer) |
| India price (approx) | ₹4,000–8,000/month (generics available) | ₹12,000–18,000/month |
| Generic available? | Yes (Indian generics from 2026) | No (patent protected) |
| Maker | Novo Nordisk | Eli Lilly |
Weight loss: Mounjaro wins
In the SURMOUNT-5 trial — the first direct head-to-head — tirzepatide (Mounjaro) produced 20.2% weight loss vs semaglutide's 13.7% over 72 weeks. That's a significant difference. Mounjaro's dual mechanism (GLP-1 + GIP) appears to drive greater appetite suppression and metabolic improvement.
However, both drugs produce clinically meaningful weight loss. For many people, 15% vs 22% is less important than cost, availability, and tolerability.
Side effects comparison
Both drugs share similar GI side effects — nausea, vomiting, diarrhea — during dose escalation. Mounjaro has a slightly lower rate of GI complaints in trials, possibly because the GIP component helps modulate nausea.
- Nausea: Ozempic ~25%, Mounjaro ~20%
- Diarrhea: Similar (~15%) for both
- Muscle loss: Both cause ~30–40% lean mass loss without intervention
- Gallbladder events: Slightly higher with Ozempic in some analyses
India pricing
This is where the decision gets practical for most Indians:
Ozempic: Indian-made generic semaglutide pens became available in early 2026. Cost dropped from ₹12,000+ to ₹4,000–8,000/month. Mounjaro: No generics yet. Imported pens cost ₹12,000–18,000/month. For many Indians, this cost difference is the deciding factor.
Which one should you choose?
Choose Ozempic (semaglutide) if:
- Cost is a factor — generics make it 2–3× cheaper
- You have type 2 diabetes (long track record, cardiovascular data)
- You need a proven drug with extensive safety data
Choose Mounjaro (tirzepatide) if:
- Maximum weight loss is your primary goal
- You can afford the higher cost
- You've tried semaglutide and plateaued
- You want potentially fewer GI side effects
Comparing GLP-1 drugs? Track your response with data.
eterni tracks your weight, HbA1c, insulin, and metabolic markers over time — so you can see which drug is actually working for your body.
Get early accessFrequently Asked Questions
Is Mounjaro better than Ozempic for weight loss?
Yes — in the SURMOUNT-5 head-to-head trial, tirzepatide (Mounjaro) produced 20.2% weight loss vs semaglutide's 13.7% over 72 weeks. The dual GLP-1/GIP mechanism appears to be more effective. However, both produce clinically meaningful results, and cost/availability may matter more than the percentage difference.
Which has fewer side effects — Ozempic or Mounjaro?
Side effects are similar, but Mounjaro showed slightly lower rates of nausea in head-to-head comparisons. Both cause GI symptoms (nausea, diarrhea, vomiting) during dose escalation that typically improve within 4–8 weeks. The side effect profiles are not different enough to be a primary decision factor for most people.
Can I switch from Ozempic to Mounjaro?
Yes, switching is common. Your doctor will typically start you at a lower Mounjaro dose and titrate up. There's no washout period needed. Some people who plateau on semaglutide see renewed weight loss after switching to tirzepatide.
Which is cheaper in India?
Ozempic (semaglutide) is significantly cheaper due to Indian generic versions available from early 2026 — roughly ₹4,000–8,000/month. Mounjaro has no generics yet and costs ₹12,000–18,000/month for imported pens. For budget-conscious users, semaglutide is the clear winner.
The science behind the difference
Semaglutide activates GLP-1 receptors only. Tirzepatide activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. GIP was originally thought to promote fat storage, but tirzepatide's clinical data suggests that at pharmacological doses, GIP agonism actually enhances fat oxidation and improves insulin sensitivity beyond what GLP-1 alone achieves.
The dual mechanism likely explains tirzepatide's superior efficacy — more appetite suppression, better insulin sensitivity, and greater metabolic improvement than GLP-1 alone.
Key trial data
- SURMOUNT-5 (head-to-head): Tirzepatide 15 mg vs semaglutide 2.4 mg. Weight loss: 20.2% vs 13.7% at 72 weeks. Tirzepatide was statistically superior.
- HbA1c: Tirzepatide produced greater HbA1c reductions (2.0–2.4% vs 1.5–1.8%) in diabetic populations.
- STEP trials (semaglutide): ~15–17% weight loss. SELECT trial showed 20% cardiovascular risk reduction — the strongest CV evidence for any GLP-1.
- SURMOUNT trials (tirzepatide): ~21–22% weight loss at highest dose. CV outcomes trial (SURPASS-CVOT) ongoing.
Know what's working. Know what's not.
eterni connects your lab results, medications, and retests — so you can see the trajectory, not just a snapshot.
Join the waitlist